BridgeBio to present Phase 3 CALIBRATE trial results for ADH1 treatment at 2026 ECE conference

BridgeBio Pharma announced it will present primary results from its Phase 3 CALIBRATE trial of encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), at the 2026 European Congress of Endocrinology in Prague. The company will share multiple presentations including oral talks and posters detailing the trial outcomes and genetic findings related to ADH1. This data is significant as it highlights potential advancements in treating a rare genetic condition with limited options. The presentations are scheduled for May 9-12, 2026, providing insights into encaleret's effectiveness and the genetic basis of ADH1.